| Previous Close | 5.0100 |
| Open | 5.0100 |
| Bid | 0.0000 x 2900 |
| Ask | 5.9300 x 800 |
| Day's Range | 4.7800 - 5.1595 |
| 52 Week Range | 3.6180 - 23.3500 |
| Volume | 237,338 |
| Avg. Volume | 323,575 |
| Market Cap | 109.35M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | 69.29 |
| EPS (TTM) | 0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TAIZHOU, China , April 17, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ( NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...
TAIZHOU, China, Apr. 2, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that its VIE subsidiary, Jiangsu Suxuantang Pharmaceutical Co., Ltd. ("Taizhou Suxuantang"), has been certified as National High-tech Enterprise (the "Certification") by the Ministry of Science and Technology of the PRC. The Certification is valid for three years and allows Taizhou Suxuantang to enjoy a preferential income tax rate of 15% versus the standard rate of 25%.
TAIZHOU, China , March 28, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, ...
Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
TAIZHOU, China and NEW YORK, Jan. 4, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced the final closing of its initial public offering on January 3, 2019. Together with the first closing on December 31, 2018, the Company raised approximately $10.2 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,546,275 ordinary shares at a public offering price of $4.00 per share. The shares are scheduled to commence trading on the NASDAQ Capital Market today at around 2:05 p.m. ET under the ticker symbol "SXTC".